Issue link: https://www.e-digitaleditions.com/i/1267517
Tablets & Capsules July 2020 35 Innovation" and were based on the design and performance of the com- plete CDC systems, recognizing Lilly's forward-looking stance and positive attitude toward innovation. As the Lilly systems demonstrate, continuous manufacturing of oral solid dosage forms has begun to impact the quality and efficiency o f p h a r m a c e u t i c a l m a n u f a c t u r - ing. According to Hanson, "The end result is that not only can the company deliver novel therapies quicker, but it can also focus on producing more cost-effective ther- apeutic treatments that will make life better for patients." T&C Eli Lilly and Company Indianapolis, IN 317 276 2000 www.lilly.com Coperion K-Tron Sewell, NJ 856 256 3119 www.coperion.com info@coperion.com ufacture of early-phase treatments in the Lilly pipeline. "Greater implementation speed has proved possible because the pro- cess scale, equipment design, and automation infrastructure are virtu- ally identical for all three plants," said Hanson. "This means that process scale-ups were eliminated, technol- ogy transfer risks reduced, and devel- opment costs were far lower than those of more traditional operations. CDC also brings supply chain flexi- bility by enabling the production of flexible batch sizes. This allows eas- ier transition from smaller batch sizes used to supply clinical trial demands to the larger batches needed for full- scale commercial supply." As a result of Lilly's dedication to process innovation, the company won the prestigious International Society for Pharmaceutical Engi- neering (ISPE) "Facility of the Year" award in 2017 for its Indianapolis and Carolina, Puerto Rico, facilities. The awards were in the categories "Facility of the Future" and "Process smooth installation, commissioning, and qualification process. Improved quality, efficiency, and flexibility In September of 2017, the FDA approved Verzenio, making it one of the first FDA-approved drug prod- ucts manufactured using a contin- uous process. Since then, Lilly has been operating its CDC systems long enough to form a clear picture of the benefits they provide, which include enhanced quality assurance, financial savings, operational efficiency gains, and increased flexibility. The CDC systems use a pro- gressive control scheme anchored by advanced automation and pro- cess analytical technology (PAT) to ensure consistent control, low process variability, and high qual- ity assurance. Replicating the CDC facilities across all three of the com- pany's lines has reduced the devel- opment and technical transfer time needed to start the commercial man- Federal Equipment Company has on-hand inventory in more than 200 categories, enabling you to source reliable processing and packaging equipment that's housed in clean, climate-controlled warehouses. We obtain most of our inventory by providing asset management programs to large, multinational companies. This gives you a wide range of options to get the leading OEM-brand equipment you need from a reputable source, and installed and operating in your facility as fast as possible. No matter what your equipment needs are, make Federal Equipment Company your first call. THINI KNOWLEDGEABLE EXPERTS When you think equipment, think Federal Equipment